Palmitoylethanolamide for Post-operative Pain Prevention
Unknown statusNot applicableNCT01491191
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Postsurgical pain becomes chronic when it lasts more then two months after surgery. A neurogenic or neuropathic pathogenesis is hypothesized for this event that reaches high rates after urologic and gynecologic surgeries. Palmitoylethanolamide (PEA) binds to mast cells and regulates pro-inflammatory factors release, without adverse events. The investigators assume that perioperative administration of PEA can reduce chronic postsurgical pain incidence of patients undergoing to urologic and gynecologic elective surgery.
Study details
- Official title
- Perioperative Use of Palmitoylethanolamide for Prevention of Chronic Postsurgical Pain in Patients Undergoing Elective Surgery.
- Conditions
- Chronic Post-operative Pain
- Interventions
- Dietary supplement: Palmitoylethanolamide
- Dietary supplement: Placebo
- Sponsor
- University of Modena and Reggio Emilia
- Start date
- 2012-01
- Primary completion
- 2013-07
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients undergoing elective gynecological or urological surgical procedures Exclusion Criteria: * age \< 18 * pregnancy or nursing * pre-existing chronic pain * severe hepatic or renal failure * post-operative progression of local cancer disease * post-operative infection or inflammation of surgical wound
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01491191